

Optimal programming in cardiac resynchronization therapy

Cengiz Ermiş

From the Cardiovascular Division, Medical School, Akdeniz University, Antalya, Turkey

ABSTRACT

Cardiac resynchronization therapy (CRT) has been shown to improve cardiac function, diminish hospitalization frequency, and enhance quality of life in selected heart failure patients. This benefit is mostly due to improved synchronization of ventricular contraction in the diseased heart. Since heart failure patients represent a heterogeneous group, cardiac resynchronization therapy must be tailored to each patient. Thus the best performance can be achieved by optimal programming of the device for each individual. This communication discusses different methods used for optimal programming for individuals who undergo CRT device implantations. (*Anadolu Kardiyol Derg 2007; 7 Suppl 1; 50-2*)

Key words: cardiac resynchronization therapy, artificial cardiac pacing, heart failure

Introduction

In patients with severe left ventricular (LV) dysfunction and intraventricular conduction disease, who are already being administered maximally tolerated pharmacological treatment for heart failure, biventricular stimulation (i.e., cardiac resynchronization therapy [CRT]) has been shown to improve cardiac function, diminish heart failure hospitalization frequency, and enhance quality of life presumably due to improved synchronization of ventricular contraction in the diseased heart (1-11).

Clinical experience

Clinical experience with biventricular and/or LV-based pacing dates from the initial case report by Cazeau et al (12). Subsequently, Blanc et al (1, 13) indicated that in acute studies both left ventricular and biventricular pacing were comparable hemodynamically, and far better than right ventricular (RV) pacing alone in patients with left ventricular dysfunction. Kass et al (14) used careful evaluation of ventricular pressure-volume loops to provide further important insight supporting this latter observation. Subsequently several controlled trials have demonstrated improvements in exercise tolerance and quality of life, and reduced hospitalization frequency associated with introduction of a biventricular pacing strategy (4, 6, 7, 15). By way of example, Abraham et al (7) concluded that biventricular pacing resulted in significant clinical improvement in patients who had both moderate-to-severe heart failure and an intraventricular conduction delay.

Mechanisms

Cardiac resynchronization therapy improves cardiac hemodynamics in heart failure patients with one or more of the

following actions (7); i) increased LV filling time, ii) decreased septal dyskinesia, increased LV dp/dt, iii) reduced mitral regurgitation.

Increased LV Filling Time

Left ventricular filling time is the diastolic filling period which starts with the beginning of the E wave (mitral flow velocity during early filling) and ends with the end of A wave (mitral flow velocity during atrial contraction). In the presence of an interventricular conduction delay LV activation is delayed whereas atrial activation is not. So, the passive filling and atrial kick occur simultaneously, resulting in shortened LV filling time and decreased preloading of LV. The related echocardiographic finding is the fusion of E and A waves. With the initiation of the biventricular pacing both ventricles activate simultaneously, thus LV becomes able to complete the contraction and begin relaxation earlier, which causes an increase in ventricular filling time. The resultant echo effect is the re-separation of the E and A waves on Doppler transmitral flow measurement.

Decreased septal dyskinesia, increased LV dp/dt

Interventricular conduction delays also disturb the normal activation contraction sequence between the septum and free wall. Free wall contracts in a time distance after the septal contraction and the resulting time mismatch causes the septum to move away from the free wall during ventricular systole diminishing the septum's contribution to LV stroke volume.

Biventricular pacing causes the septal and free walls to activate synchronously. This allows ventricular ejection to occur prior to relaxation of septum improving the stroke volume and other systolic indices like LV dp/dt.

Reduced mitral regurgitation

Normal mitral valve opening and closure depends on an appropriately timed atrial and ventricular contraction. In the

presence of an interventricular (VV) and atrioventricular (AV) conduction delays, mitral valve closure may not be complete. If the time lag is long enough ventriculo-atrial pressure gradient may cause diastolic mitral regurgitation. By resynchronizing atrioventricular and interventricular activation mitral regurgitation is reduced or eliminated.

Optimal programming

Since heart failure patients represent a heterogeneous group, cardiac resynchronization therapy must be tailored to each patient. Thus the best performance can be achieved by optimal programming of the device for each individual. Three main components of the optimal programming are; i) pacing both the right and left ventricles, ii) optimizing the AV delay, iii) optimizing the VV delay.

Pacing both the right and the left ventricles

Selecting a left ventricular pacing site that best corrects the electromechanical delay within the LV is the first step and the key to provide effective biventricular pacing. Early studies have shown that pacing at sites of latest activation of the LV provides the greatest improvement in pulse pressure and LV dp/dt (1, 4, 7). When the LV lead tip is at the latest site of activation, the LV electrogram signal will intersect the latter part of QRS on surface electrocardiogram (ECG).

The position of the right ventricular lead relevant to LV lead is another important consideration. Optimally the RV lead is positioned as far away from the LV lead as possible. Maximizing this distance not only reduces the risk of far-field sensing but also improves effectiveness of biventricular pacing. In this regard, the position of the LV lead in the lateral (marginal) and posterolateral veins have shown to provide the most effective biventricular pacing.

Optimizing the AV delay

Achieving an optimized AV delay adjusts the contraction sequence between the left atrium and the left ventricle to optimize left ventricular filling without truncating atrial contribution. Optimal AV delay optimizes stroke volume and minimizes mitral regurgitation. There are several methods to determine optimal AV delay.

The first one is empirical calculation where the optimal AV time is calculated as the half of the sensed PR interval minus 20.

One more complicated formulation is the Ritter technique (17). In this technique, one obtains a pulsed wave Doppler view of trans-mitral flow via a 4-chamber view. As the ECG, E-wave and A-wave recordings are visualized, a short sensed AV interval (AVShort) is programmed, and the corresponding QA (QAShort) is measured. Next, the long sensed AV interval (AVLong) is programmed and the corresponding QA (QALong) is measured. The optimal AV is then calculated as follows;

$$AV_{opt} = AV_{short} + [(AV_{long} + QA_{long}) - (AV_{short} + QA_{short})].$$

The third method is the iterative method where the operator starts with an AV delay programming that causes ventricular pre-excitation. Then the programmed AV delay is decreased until the A-wave begins to truncate. Subsequently the AV delay is increased until the completion of the A-wave contribution is seen. That specific time frame is then taken as the optimal AV delay.

The fourth and last method is the pulse pressure method where an arterial line is utilized to measure the central aortic pressure accurately. The AV delay programming starts at a lower value and then delay is increased progressively to get an optimal value that provides maximal difference between systolic and diastolic blood pressures.

Optimizing the VV delay

Optimizing the pacing timing between two ventricles helps to adjust contraction sequence between the left and right ventricles, ideally optimizing the left to produce the largest stroke volume in certain patients. The optimal Velocity Time Integral (VTI), which is a surrogate for stroke volume, is used to determine an optimal VV delay setting.

In this technique, Doppler velocities across the aortic valve are obtained using the apical long axis view. Either a continuous or pulse wave Doppler velocity can be used hence both have advantages and disadvantages. Then the VTI values, as the area under velocity time curve, are calculated. The multiplication of the VTI with the LV outflow tract area gives the stroke volume, thus a larger VTI represents a greater stroke volume.

For different VV settings all VTI values are calculated next, without moving the sample volume on Doppler echocardiogram. Two to three VTI values are measured for each VV setting and an average value is taken. The greatest VTI with maximal stroke volume is determined and the associated setting is accepted as the optimal VV delay for that given patient.

Conclusion

Cardiac resynchronization therapy offers a significant morbidity and mortality benefit for patients suffering from severe congestive heart failure. However, there are some issues still waiting to be resolved like, prediction of responders vs. nonresponders. We believe that the achievements in tailoring of the therapy to different individuals may help to shed light on these issues and undoubtedly, an optimal programming of these devices may be the key for this purpose.

References

1. Blanc JJ, Etienne Y, Gilard M, Mansourati J, Munier S, Boschat J, et al. Evaluation of different ventricular pacing sites in patients with severe heart failure. Results of an acute hemodynamic study. *Circulation* 1997; 96: 3273-7.
2. Leclercq C, Cazeau S, Le Breton H, Ritter P, Mabo P, Gras D, et al. Acute hemodynamic effects of biventricular DDD pacing in patients with end-stage heart failure. *J Am Coll Cardiol* 1998; 32: 1825-31.
3. Etienne Y, Mansourati J, Gilard M, Valls-Bertault V, Boschat J, Benditt DG, et al. Evaluation of left ventricular based pacing in patients with congestive heart failure and atrial fibrillation. *Am J Cardiol* 1999; 83: 1138-40.
4. Cazeau S, Leclercq C, Lavergne T, Walker S, Varma C, Linde C, et al; Multisite Stimulation in Cardiomyopathies (MUSTIC) Study Investigators. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. *New Engl J Med* 2001; 344: 873-80.
5. Nelson GS, Berger RD, Fetters BJ, Talbot M, Spinelli JC, Hare JM, et al. Left ventricular or biventricular pacing improves cardiac function at diminished energy cost in patients with dilated cardiomyopathy and left-bundle branch block. *Circulation* 2000; 102: 3053-9.

6. Mansourati J, Etienne Y, Gilard M, Valls Bertault V, Bosch J, Benditt DG, et al. Left ventricular-based pacing in patients with chronic heart failure: comparison of acute hemodynamic benefits according to underlying heart disease. *Eur J Heart Fail* 2000; 2: 195-9.
7. Auricchio A, Stellbrink C, Sack S, Block M, Vogt J, Bakker P, et al; Pacing Therapies in Congestive Heart Failure (PATH-CHF) Study Group. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. *J Am Coll Cardiol* 2002; 39: 2026-33.
8. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, et al; MIRACLE Study Group. Multicenter InSync Randomized Clinical Evaluation. Cardiac resynchronization in chronic heart failure. *N Engl J Med* 2002; 346: 1845-53.
9. Higgins SL, Hummel JD, Niazi IK, Giudici MC, Worley SJ, Saxon LA, et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. *J Am Coll Cardiol* 2003; 42: 1454-59.
10. Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B, et al; Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE ICD) Trial Investigators. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. *JAMA* 2003; 289: 2685-94.
11. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. *New Engl J Med* 2004; 350: 2140-50.
12. Cazeau S, Ritter P, Lazarus A, Gras D, Backdach H, Mundler O, et al. Multisite pacing for end-stage heart failure: early experience. *Pacing Clin Electrophysiol* 1996; 19: 1748-57.
13. Blanc JJ, Benditt DG, Gilard M, Etienne Y, Mansourati J, Lurie KG. A method for permanent transvenous left ventricular pacing. *Pacing Clin Electrophysiol* 1998; 21: 2021-24.
14. Kass DA, Chen CH, Curry C, Talbot M, Berger R, Fetters B, et al. Improved left ventricular mechanics from acute VDD pacing in patients with dilated cardiomyopathy and ventricular conduction delay. *Circulation* 1999; 99: 1567-73.
15. Braunschweig F, Linde C, Gadler F, Ryden L. Reduction of hospital days by biventricular pacing. *Eur J Heart Fail* 2000; 2: 399-406.
16. Medina Ravell VA, Lankipalli RS, Yan GX, Antzelevitch C, Medina-Malpica NA, Medina-Malpica OA, et al. Effect of epicardial or biventricular pacing to prolong QT interval and increase transmural dispersion of repolarization: does resynchronization therapy pose a risk for patients predisposed to long QT or torsade de pointes? *Circulation* 2003; 107: 740-6.
17. Ritter P, Dib JC, Lellevre T. Quick determination of the optimal AV delay at rest in patient paced in DDD mode for complete AV block (abstract). *Eur J Cardiac Pacing Electrophysiol* 1994; 4: A163.